Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells (MS 2023) - Apellis Medical Hub Canada

Pegcetacoplan in Geographic Atrophy: 24-Month Efficacy Results From the Phase 3 OAKS and DERBY Trials – Impact on Retinal Cells

Share Via Email

Back to Conference Resources

GA Congress Presentations Macula Society 2023

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.